#National Institute of Neurological Disorders and Stroke

[simonh]

Gene Discovery In the Human Genome by National Library of Medicine Via Flickr: Contributor(s): Venter, J. Craig. National Institutes of Health (U.S.). Medical Arts and Photography Branch. Publication: [Bethesda, Md. : Medical Arts and Photography Branch, National Institutes of Health], 1992 Language(s): English Format: Still image Subject(s): DNA, Genome, Human Genre(s): Posters Abstract: The poster is black with the computerized view of DNA bands taking up three-quarters of the area. The remainder of the poster gives the title and Dr. Venter's position as Chief, Receptor Biochemistry and Molecular Biology Section, National Institute of Neurological Disorders and Stroke, NIH. The date of the lecture is Thursday, July 23, 1992, and the time and place are also listed. A phone number and contact name for additional information are also given. Extent: 1 photomechanical print (poster) : 79 x 55 cm. Technique: color NLM Unique ID: 101454172 NLM Image ID: C00799 Permanent Link: resource.nlm.nih.gov/101454172

[mindblowingscience]

In 2016, years before long COVID was a thing, the US National Institutes of Health, the largest single public funder of medical research in the world, launched a study into a long-neglected and puzzling condition: chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, or ME/CFS. Eight years later, the results of that study are finally out. In one of the most thorough investigations to date, researchers took a deep dive into a small group of 17 people who developed ME/CFS after an infection and found distinct biological differences compared to 21 healthy controls. "Overall, what we show is that ME/CFS is unambiguously biological, with multiple organ systems affected," neurologist Avindra Nath, lead researcher of the study and clinical director of NIH's National Institute of Neurological Disorders and Stroke (NINDS), said in an interview with JAMA. For decades, many doctors had dismissed ME/CFS as a psychosomatic condition that was 'all in patients' heads'. Now there is little doubt: a host of biological changes underpin ME/CFS.

Continue Reading.

[kira-akira]

Bernie Sanders Introduces Long COVID Moonshot Legislation

This legislation "provides $1 billion in mandatory funding per year for 10 years to the National Institutes of Health (NIH) to support Long COVID research, the urgent pursuit of treatments, and the expansion of care for patients across the country." Announcement on Sander's twitter and the Long COVID Moonshot website.

This announcement references the number 22 million for adults affected by Long COVID in the US but that number is certainly much higher; in 2022 the CDC reported that 7.5% of US adults have Long COVID and that number can only have increased.

Here is an article published today on PBS if you need a primer or a refresher on what Long COVID is and why everyone needs to care about it. From the article:

"Long COVID is a complex chronic condition that can result in more than 200 health effects across multiple body systems. These include:

Heart disease

Neurologic problems such as cognitive impairment, strokes and dysautonomia. This is a category of disorders that affect the body’s autonomic nervous system – nerves that regulate most of the body’s vital mechanisms such as blood pressure, heart rate and temperature.

Post-exertional malaise, a state of severe exhaustion that may happen after even minor activity — often leaving the patient unable to function for hours, days or weeks

Gastrointestinal disorders

Kidney disease

Metabolic disorders such as diabetes and hyperlipidemia, or a rise in bad cholesterol

Immune dysfunction"

I know it's easy to give into despair but THERE IS HOPE for the future! For decreasing transmission of COVID-19, for developing preventatives against Long COVID, and for treating Long COVID. To highlight just a few of the possible pathways to prevention and treatment being currently researched:

The possibility of using antivirals to treat not just Long COVID but any autoimmune disease

The development of N95 masks that can sense SARS-CoV-2 in exhaled breath using a printed immunosensor

A nasal vaccine that halts transmission of SARS-CoV-2 (though does not stop the user from developing COVID-19)

A Japanese research team is looking to treat COVID-19 by using embryonic stem cells to target the virus

The possibility of using already-developed arthritis drugs to treat Long COVID respiratory symptoms

Researchers just identified a possible protein to target in treating Long COVID fatigue

This is an incredibly small collection of studies researching potential treatments but they themselves and the decades of research they are built on had to be funded. In fact, since the pandemic began, more than 24,000 scientific publications about COVID-19 have been published, making it the most researched health condition in any four years of recorded human history.

So there is hope! But all this research needs money. Money that Long COVID Moonshot will provide. And while we wait for research to bear fruit, that $1 billion per year will also be crucial in caring for those suffering from Long COVID in the meantime.

So What Can You Do?

Keep masking - We've just hit 900,000 new COVID cases per day in the US and this wave is not even at its peak yet (For reference, Fauci stated back in 2021 that getting under 10,000 cases per day would allow for mask mandates and safety measures to relax...)

Go on the Long COVID Moonshot website and write to your legislators in support (You can use their script, it only takes 1 minute!)

Keep yourselves and others informed - On the Moonshot website they also offer handy graphics and facts sheets that you can post wherever you can. Spread the word!

And if you or someone you know has Long COVID, you can write in to the Long COVID Moonshot website about your experience

And remember, no one is safe from Long COVID; your chances of developing Long COVID increase with every reinfection. Until research like what Long COVID Moonshot will fund discovers viable preventatives and treatments, the only way to not get Long COVID is to not get COVID-19 in the first place.

Stay safe, stay hopeful, support Long COVID Moonshot, and mask up!

[partisan-by-default]

Multiple sources at the NIH, granted anonymity because they were not authorized to talk to the media, confirmed Tuesday afternoon that at least 10 principal investigators who were leading and directing medical research at the agency had been fired. Among them is Dr. Richard Youle, a leading researcher in the field of neurodegenerative disorders previously awarded the Breakthrough Prize in Life Sciences for his groundbreaking research identifying mechanisms behind Parkinson’s disease.

The Breakthrough Prize ceremony, often referred to as the “Oscars of Science,” was last year attended by Elon Musk, whose Department of Government Efficiency (DOGE) has served as the tip of the spear in President Donald Trump’s campaign to eliminate large swaths of the federal workforce.

HHS did not respond to WIRED's questions about the firings of NIH scientists. Vianca Rodriguez, an agency spokesperson, pointed to previous statements by Secretary Kennedy, including plans announced last week to eliminate 1,200 NIH jobs in areas of procurement, human resources, and communications.

Multiple NIH sources tell WIRED the layoffs include—in addition to labor, IT, and human resources personnel—several accomplished senior investigators at the National Institute of Neurological Disorders and Stroke (NINDS), top scientists at the National Institute on Aging, and several researchers noted for their work in HIV, emerging infectious diseases, and child brain and neural disorders.

[mariacallous]

Several top scientists charged with overseeing research into disease prevention and cures at the National Institutes of Health (NIH) were notified that they were subject to a reduction in force on Tuesday as part of a devastating purge of federal employees carried out by US Health and Human Services secretary Robert Kennedy Jr., WIRED has learned.

Multiple sources at the NIH, granted anonymity because they were not authorized to talk to the media, confirmed Tuesday afternoon that at least 10 principal investigators who were leading and directing medical research at the agency had been fired. Among them is Dr. Richard Youle, a leading researcher in the field of neurodegenerative disorders previously awarded the Breakthrough Prize in Life Sciences for his groundbreaking research identifying mechanisms behind Parkinson’s disease.

The Breakthrough Prize ceremony, often referred to as the “Oscars of Science,” was last year attended by Elon Musk, whose Department of Government Efficiency (DOGE) has served as the tip of the spear in President Donald Trump’s campaign to eliminate large swaths of the federal workforce.

HHS did not respond to WIRED's questions about the firings of NIH scientists. Vianca Rodriguez, an agency spokesperson, pointed to previous statements by Secretary Kennedy, including plans announced last week to eliminate 1,200 NIH jobs in areas of procurement, human resources, and communications.

Multiple NIH sources tell WIRED the layoffs include—in addition to labor, IT, and human resources personnel—several accomplished senior investigators at the National Institute of Neurological Disorders and Stroke (NINDS), top scientists at the National Institute on Aging, and several researchers noted for their work in HIV, emerging infectious diseases, and child brain and neural disorders.

At an NINDS town hall meeting on Tuesday, leadership at that institute expressed confusion about the cuts, saying they were blindsided by firings of principal investigators, or PIs, who lead research teams. NIH has approximately 1,200 PIs across its 27 centers and institutes. “To get rid of 11 of our senior PIs … we’re hoping that’s a mistake, because we can’t figure out why they would want to do that,” said Walter Koroshetz, director of the NINDS, according to a source present at the meeting.

The labs affected by the layoffs include those involved in clinical trials as well as preclinical studies. It is unclear, NIH staff said, what the plans are for the data they've accumulated or what will happen to patients involved in ongoing trials.

An email sent out Tuesday to more than 2,000 recent college graduates, graduate students, and postdoctoral fellows working at NIH seems to confirm the firings of multiple PIs. “Many of us know someone, directly or indirectly, who received a termination notice today as part of an HHS-wide Reduction in Force,” reads an email by Sharon Milgram, director of NIH’s Office of Intramural Training & Education, which was shared with WIRED.

The NIH supports young researchers through various programs, typically temporary one- or two-years fellowships. These early-career scientists are placed in labs under a PI. In her email, Milgram tells fellows with NIH’s postbaccalaureate, cancer research, and visiting fellows programs whose PI received an RIF notice, “I can assure you that your fellowship appointment is not immediately terminated and that we will work with each of you to explore reassignment options soon.”

An effort is said to be underway by NIH leaders to reverse the firings of the investigators, whose absence, sources say, could paralyze research at the agency into finding targets and biomarkers for drug development and other treatment.

The Trump administration sent out notices to thousands of federal health agency employees Tuesday, including at the NIH, the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC).

The NIH, which serves as the world's largest source of funding for research into the causes, prevention, and cure of human disease, was stripped of critical support staff on Tuesday in what Health Secretary Kennedy framed as a shift in his agency's priorities. Roughly a quarter of the agency's staff has been cut since the start of Trump's second term.

In a statement on X, Kennedy called the firings a "difficult moment," while blaming the size of his department's budget. "This overhaul is about realigning HHS with its core mission to stop the chronic disease epidemic and Make America Healthy Again," he said.

A senior scientist at NIH tells WIRED the impact of Tuesday's layoffs was sheer "chaos," with the firings of the lead investigators projected to widely impair and impede diverse ongoing research ranging from mechanisms within cells in the brain to human patients with neurologic conditions.

"It's extremely disruptive to lose the head of a lab," another scientist said. "But this is also disruptive for every single lab that does remain at NIH, because they've removed so much of the administrative support that's necessary for us to function."

On Tuesday, US Senators Bill Cassidy, a Republican from Louisiana, and Bernie Sanders, an independent from Vermont, sent a letter to Kennedy inviting him to an April 10 Senate Health, Education, Labor, and Pensions (HELP) Committee meeting on the HHS reorganization.

During his confirmation process, Kennedy committed to providing quarterly updates to the HELP committee, which Cassidy chairs. “This will be a good opportunity for him to set the record straight,” Cassidy said in a statement, “and speak to the goals, structure and benefits of the proposed reorganization.”

[peri-bee-fairywinkle]

(NOT A ROLEPLAY POST)

As some of you may know, Peri in my FOPANW AU is diagnosed with a magical variant of FND or Functional Neurological Disorder called F-FND (or Fairy Functional Neurological Disorder). I decided to do this because I personally have FND and I wanted to project onto Peri.

SO, long story short I decided to make an infographic about F-FND because why not.

Below I have copied all the text from my infographic for access and for those who didn't want to read it with the purple background lol.

| | | V

This is a Fairly Oddparents Headcanon, and not a real condition! Based on Functional Neurological Disorder (FND) which is a real condition that affects real people. Do not rely on this for grounds of self-diagnosis!

What is F-FND?

Similar to FND in humans, F-FND is a neurological condition caused by changes in the brain’s network, and faulty signals, rather than the brain’s physical composition.

F-FND is a disorder that also affects magic ability, and can increase the risk of magical backup and magical burnout.

What causes it?

Contrary to historical belief, the cause of F-FND remains unknown. Some fairies argue that it’s triggered by psychologically or physically traumatic events, however this has been disproven.

Symptoms include but are not limited to:

Involuntary bursts of magic that aren’t dissimilar to tics, and also regular tics too.

Pain, including chronic migraines

Seizure-like episodes which may involve loss of consciousness and full or partial body convulsions and shaking as well as other symptoms.*

Dissociative seizures, where one may feel disconnected from their thoughts, feelings and/or environment.

Fatigue

Dizziness

Limb weakness or paralysis

Dystonia (When a muscle contracts involuntarily for a prolonged period of time)

Sources

National Institute of Neurological Disorders and Stroke. “Functional Neurological Disorder | National Institute of Neurological Disorders and Stroke.” Www.ninds.nih.gov, 8 Jan. 2024, www.ninds.nih.gov/health-information/disorders/functional-neurologic-disorder.

Stone, Jon. “Functional Neurological Disorder (FND) – a Patient’s Guide to FND.” FND Guide, neurosymptoms.org/en/.

FND Hope. “Cognitive Changes.” FND Hope International, 2021, fndhope.org/fnd-guide/symptoms/cognitive-changes/.

Myself (Despite not knowing everything about this condition, I am diagnosed with FND [the human variety]  and am writing a lot from my own experiences. Thankfully, I do not experience functional seizures but I am trying my best to research as much as I can.)

Anyway I hope this is helpful??? I don't know why I made this. World building I guess.

[darkmaga-returns]

Pain is the most common reason for seeking medical care.  Although pain is experienced only by individuals, under federal policy, pain is a public health challenge, even a global health priority.  In a way, this isn’t surprising, as modern definitions of health and public health are expansive, even including transitory mental and emotional states.

Public health as a concept arose along with eugenics during the Progressive Era.  Although the two concepts weren’t completely congruent, both were compatible with government assuming authority to act on behalf of the health of the population.

Logically, a healthy community isn’t a thing.  All populations include some individuals with disease or infirmity.  But the concept of public health offers an opportunity for authoritarian control.  Health-linked government actions extend beyond reasonable efforts like  sanitation, clean water, and emergency stockpiles for disasters or epidemics.

Since 2010, the National Pain Strategy, created by the NIH and Institute of Medicine (IOM) has been our government’s “comprehensive population health-level strategy for pain.”  The Federal Pain Research Strategy (FPRS) was added later.  Congress has a Best Practices Inter-Agency Task Force to align with the NPS.  The NIH has an Office of Pain Policy.  The National Institute of Neurological Disorders and Stroke has an Office of Pain Policy and Planning.

The Executive Summary of the FPRS lists these priorities: “dissemination and implementation of research to support the translation of scientific discoveries into clinical practice and improve the lives of people in pain.”  The IOM anticipates “cultural transformation in pain prevention, care, education and research” via population-level strategy.

[covid-safer-hotties]

Also preserved in our archive

NIH recently received approval to reallocate $147 million to support ongoing efforts of the Researching COVID to Enhance Recovery (RECOVER) Initiative(link is external). This allocation is in addition to the $515 million that NIH announced earlier this year, bringing total new funding to $662 million.

These funds add to the $1.15 billion that Congress appropriated in 2021 to support the establishment of the RECOVER nationwide research program. To date, the program is conducting large, multi-site observational studies with more than 40,000 participants. The adult cohort has donated more than 822,000 biospecimens, and the pediatric cohort has donated more than 85,000 biospecimens – all accessible through the RECOVER biorepository for further studies within and beyond RECOVER. In addition, RECOVER supports 40 existing pathobiology studies to understand the biological mechanism of disease, ongoing studies evaluating 60 million electronic health records, and eight existing phase 2 clinical trials testing the safety and efficacy of 13 treatments that include drugs, biologics, medical devices, and other therapies.

In July, NIH began planning for the next phase of long COVID clinical trials through a newly launched program called RECOVER-Treating Long COVID (RECOVER-TLC(link is external)). NIH’s National Institute of Allergy and Infectious Diseases is leading the program in partnership with the Foundation for the National Institutes of Health and in collaboration with NIH’s National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke.

The $662 million in funds will be allocated over Fiscal Years 2025-2029 to support the following research areas:

RECOVER-TLC clinical trials Completion of adult and pediatric observational studies Additional pathobiology studies to examine how long COVID affects different parts of the body which will help to inform clinical trials Preservation and broader access to data and biospecimens and maintaining RECOVER-supported research infrastructure over the next five years Update on Progress RECOVER-TLC RECOVER will allocate approximately $300 million to RECOVER-TLC clinical trials. In September 2024, NIH convened more than 1400 patients, advocates, health care providers, and scientists from academia and pharmaceutical and biotech industries to discuss research priorities and plans for clinical trials that are most needed. During the three-day workshop(link is external), participants discussed a variety of topics, including pathobiology, biomarkers, epidemiology and cohort studies, clinical trial designs, interventional prioritization strategies, and endpoint selection. Importantly, participants at the workshop emphasized the importance of meaningful engagement and collaboration with people affected by Long COVID. NIH plans to convene another workshop and a series of webinars in 2025.

In October, NIH issued a Request For Information to gather ideas on candidate pharmacologic and non-pharmacologic interventions for this next phase of trials, which will remain open until Feb. 1, 2025. Additionally, NIH opened a portal(link is external) for idea submission for therapeutics and biologics and established a review process for vetting these ideas.

RECOVER-TLC will design nimble clinical trials with direct and transparent engagement with scientific, industry, and patient communities. RECOVER-TLC will continue to provide access and sharing of deidentified data with public and scientific communities.

New pathobiology awards RECOVER will award nearly $18 million from the initial $1.15 billion for an additional 20 pathobiology research projects. Pathobiology studies look at biological mechanisms—processes that take place inside the body and its cells—of long COVID. This research is advancing our understanding of the changes in tissues and organs that are caused by SARS-CoV-2 infection and identifying biological markers for therapeutic target based on individuals’ risk factors.

By examining biospecimens such as blood, saliva and other samples and data collected from RECOVER cohorts and clinical trial participants, the new pathobiology studies will help us better understand the 200 conditions associated with long COVID, including:

The effects of COVID-19 on the respiratory, vascular, and other body systems How long COVID compares with other infection-associated chronic conditions The remaining gaps in knowledge of tissue-specific manifestations, including molecular mechanisms such as dysregulation or disruption of normal physiologic pathways These sub-awards build on the more than 40 pathobiology research projects(link is external) awarded in 2022 that are yielding important results. For example, one study found that severe COVID-19 may cause long-lasting alterations to the innate immune system, the first line of defense against pathogens, making some people susceptible to other infections. Another study found that symptoms for some long COVID sufferers appear to be caused by persistent infection and may respond to antiviral medications.

Long COVID is a complex and debilitating chronic condition affecting people’s ability to work, attend school, and participate in their regular activities. Alleviating the suffering of so many individuals, their families, and their caregivers is a priority of NIH. We look forward to further advancing our understanding of long COVID and advancing prevention and treatment.

Monica M. Bertagnolli, M.D. Director, National Institutes of Health

[leaderintitleonly]

Hi. Friendly reminder. I have this:

Complex Regional Pain Syndrome And here are some resources if you're having trouble understanding what I'm going through.

RSDSA Mayo Clinic National Institute of Neurological Disorders and Stroke Stanford Medicine

We don't know if I have type 1 or type 2. We're pretty sure I have type 2 (causalgia). It's still CRPS. I take ketamine infusions. You may have heard how that helps people The pain is worse than getting a limb sawed off without medication. That's what I'm going through right now. I need you to understand this. I am struggling to do my daily chores and I am also unable to do things like take care of myself. I am trying my best all while my mental health is in the garbage. Please be kind. I'm aware I'm 3+ years behind on things but the person behind this and my associated accounts is fighting with a condition that won't ever go away and will ultimately be part of what ends me. If I move too slow for you and you're not cool with me doing short hand, I'm not mad if you unfollow. You just have to understand I am really, really struggling in my life and I have to put myself first before I get online. And sadly that sometimes means I don't log in for a while because I am really sick and in bed after doing things as simple as brushing my teeth. You're fine. Just please reevaluate if I am the rper for you.

[industrystudyreport]

Narcolepsy Therapeutics Market Growth Supported by Technological Advancements

The global narcolepsy therapeutics market was valued at USD 3.28 billion in 2022. Projections indicate a rise to USD 6.01 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 7.85% from 2023 to 2030.

Narcolepsy is a chronic sleep disorder characterized by sudden, irresistible sleep attacks, significantly impacting a patient's daily life. Several factors are fueling the market's expansion, including the increasing incidence of the disease, a surge in research and development (R&D) activities and investments, and the introduction of innovative therapeutic products. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that between 135,000 and 200,000 individuals in the U.S. are affected by narcolepsy. The disease's prevalence is expected to climb in the coming years due to rising stress levels contributing to its onset.

Increased R&D efforts aimed at developing novel treatments for narcolepsy are a significant market driver. These activities have accelerated in recent years, promising new treatment options. For example, in May 2021, Takeda Pharmaceutical Company Limited initiated R&D for narcolepsy drug candidates, with an anticipated market approval application by March 2025. Furthermore, the availability of recently approved medications is boosting the prescription of new drugs, offering improved treatment choices. An instance of this is the U.S. FDA's approval of Xywav in July 2020 for the treatment of narcolepsy in patients aged seven years and older.

Key Market Insights:

North America led the narcolepsy therapeutics market in terms of revenue in 2022, capturing a 38.03% share. This dominance is attributed to increased R&D activities and effective collaborations among research institutions, academic bodies, and the corporate sector within the region.

By treatment type, Narcolepsy with Cataplexy was the largest segment by revenue in 2022, holding a 54.28% market share. This is due to the growing prevalence of cataplexy as a primary symptom in narcolepsy patients and the increasing adoption of novel medications like WAKIX, Xyrem, and Xywav for its treatment.

In terms of product, the Sodium Oxybate segment dominated the market in 2022 with a revenue share of 46.70% and is projected to experience the fastest CAGR during the forecast period. High prescription rates, the substantial cost of these drugs, the presence of favorable reimbursement policies, and rising awareness regarding diagnosis and associated treatments are expected to drive the segment's growth.

Order a free sample PDF of the Narcolepsy Therapeutics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

2022 Market Size: USD 3.28 Billion

2030 Projected Market Size: USD 6.01 Billion

CAGR (2023-2030): 7.85%

North America: Largest market in 2022

Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Market participants are actively pursuing strategies such as product launches, acquisitions, and strategic collaborations to strengthen their market presence. For example, in May 2023, Avadel Pharmaceuticals secured final U.S. FDA approval for Lumryz, a treatment for narcolepsy. Likewise, in May 2022, Axsome Therapeutics, Inc. completed the acquisition of Sunosi from Jazz Pharmaceuticals, further expanding its U.S. portfolio. Additionally, several companies are enhancing patient access and boosting market penetration through initiatives like reduced out-of-pocket costs and free product offerings for eligible individuals. Jazz Pharmaceuticals, for instance, has implemented Patient Assistance Programs to support patients lacking sufficient insurance coverage for prescribed therapies.

Key Players

Teva Pharmaceutical Industries Ltd.

Jazz Pharmaceuticals, Inc.

Harmony Biosciences

Novartis AG

Rhodes Pharmaceuticals L.P.

Janssen Global Services, LLC

Eli Lilly and Company

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The narcolepsy therapeutics market is experiencing significant growth, driven by an increasing prevalence of the condition, intensified research and development efforts, and the introduction of new treatments. North America currently leads the market, with narcolepsy with cataplexy being the dominant treatment segment and sodium oxybate as the leading product. Market expansion is further supported by government initiatives, funding, and awareness programs, with major pharmaceutical companies actively expanding their presence through strategic product launches and acquisitions.

[nhakhoaquoctevietphapvn]

Nhức răng đau nửa đầu phải làm sao? 5+ nguy cơ biến chứng cần biết

Tình trạng đau răng lan lên đầu khá phổ biến, nhưng không phải ai cũng hiểu rõ nguyên nhân và mức độ nguy hiểm của triệu chứng này. Vậy đau răng và đau đầu có liên quan gì đến nhau? Nhức răng đau nửa đầu phải làm sao để giảm đau hiệu quả và ngăn ngừa biến chứng? Hãy cùng Nha khoa Quốc tế Việt Pháp tìm hiểu ngay trong bài viết sau đây.. 

1. Mối quan hệ giữa nhức răng và đau nửa đầu phải

Nhức răng không chỉ gây khó chịu tại chỗ mà còn có thể dẫn đến đau đầu, thậm chí đau nửa đầu. Nguyên nhân xuất phát từ mối liên hệ chặt chẽ giữa răng và hệ thần kinh, đặc biệt là dây thần kinh sinh ba – dây thần kinh cảm giác lớn nhất ở vùng đầu, chịu trách nhiệm chi phối cảm giác cho răng, nướu, môi trên, môi dưới và một phần mặt.

Khi răng bị đau do sâu răng, viêm tủy hay tổn thương, tín hiệu đau có thể kích thích dây thần kinh sinh ba, từ đó lan lên vùng đầu, gây ra đau nhức, đặc biệt là đau nửa đầu cùng bên với răng bị ảnh hưởng. 

Nhiều nghiên cứu về CGRP và cơ chế đau đầu tam thoa của Hiệp hội Đau đầu Quốc tế (International Headache Society) và Viện Rối loạn Thần kinh và Đột quỵ Quốc gia Hoa Kỳ (National Institute of Neurological Disorders and Stroke) cũng đưa ra kết luận, kích thích từ dây thần kinh sinh ba có thể làm tăng nguy cơ mắc chứng đau nửa đầu, kèm theo triệu chứng buồn nôn, nhạy cảm với ánh sáng và âm thanh. Đặc biệt, các vấn đề về răng khôn, viêm nha chu hoặc khớp thái dương hàm cũng có thể khiến cơn đau lan tỏa trên phạm vi rộng hơn, đi từ vùng miệng lên đầu.

>>> Xem thêm: https://nhakhoaquoctevietphap.vn/kien-thuc/nha-khoa-tong-quat/nhuc-rang-dau-nua-dau-phai-lam-sao.html

[treatnow]

Coming to Scientific Grips with CTE

Chronic Traumatic Encephalopathy (CTE) can only be definitively diagnosed after death through brain examination. While it is impossible to know exactly how many people are living with CTE, studies suggest a significant number of individuals with a history of repetitive head impacts, particularly in contact sports and the military, may be living with CTE or experiencing symptoms related to it.  The Boston University CTE Center has diagnosed 345 former NFL players with chronic traumatic encephalopathy (CTE) out of 376 former players studied (91.7 percent). In October 2022 the National Institutes of Neurological Disorders and Stroke (NINDS), a branch of the National Institutes of Health (NIH), updated their position on what causes CTE: “CTE is a delayed neurodegenerative disorder that was initially identified in postmortem brains and, research-to-date suggests, is caused in part by repeated traumatic brain injuries.” Of 2000 former NFL players recently interviewed, one out of three thought they had CTE. They pointed to symptoms they know plagued NFL players who committed suicide and were later found to have CTE. They reported suicidal thoughts, cognitive problems, a higher proportion of low testosterone, depression, headaches, and chronic pain. Families talked about memory loss, mood disorders, aggression, disorientation, and cognitive decline. Some started early, others went downhill years after the trauma. So what is it? How real are the symptoms that have spooked athletes, young and old? And what is the medical community, the Teams, and colleges, and the military doing in addition to keeping a scorecard of deaths? What We Think We Know About CTE - CTE is a progressive neurodegenerative disease linked to repetitive head trauma, often seen in athletes, military veterans, and others exposed to repeated brain injuries. - It’s characterized by the accumulation of "tangles" and abnormal tau protein in specific brain regions, which disrupts normal brain function. - Symptoms like the above can be subtle or aggressive, and some are familiar to those suffering from Parkinson's and Alzheimer's.  Diagnosis: Still Postmortem—But Progress Is Happening - Currently, CTE can only be definitively diagnosed after death through brain tissue analysis. - However, researchers are developing biomarkers and imaging techniques to detect signs of CTE in living individuals. A 2024 study made progress by linking behavioral symptoms (e.g., aggression or depression, mood swings and impulsivity) to tau buildup, bringing us closer to a living diagnosis.  New Discoveries - A potential new subtype of CTE—called cortical-sparing CTE (CSCTE)—was recently identified. It features tau buildup in different brain regions and may present with less cognitive impairment but earlier behavioral symptoms. - This suggests CTE may not be a one-size-fits-all disease, and personalized diagnostic and treatment approaches could be on the horizon.  Treatment and Prevention - Conventional medicine says there’s no cure yet. Symptom management includes therapy, medication, and lifestyle interventions. "Watchful waiting" is common alongside drugs. - Prevention efforts focus on reducing head impacts, especially in youth sports and high-risk professions. Youth Sports: A Wake-Up Call A 2023 study found that over 40% of young contact sport athletes (under age 30) who donated their brains postmortem had signs of CTE—even though most only played at the amateur level. The JAMA study examined 152 brains of athletes who died before the age of 30 and had been exposed to repetitive head impacts from contact sports. Of those, 63 individuals (about 41%) were diagnosed with CTE at autopsy. Here are a few key takeaways from the study: - Most of the athletes played football, followed by soccer and ice hockey. - The majority were amateur athletes—youth, high school, or college level—not professionals. - One of the cases included the first American female athlete diagnosed with CTE: a 28-year-old soccer player. - While many of the donors had symptoms like depression or apathy, not all symptomatic athletes had CTE, and the study emphasized that symptoms alone aren’t definitive indicators. The study challenges the assumption that CTE is only a risk for long-term professionals and might lead to a range of changes to limit head contact sports until later ages. A REFLECTION on a Related Case of "Failure to Inform" Watching 20 years of research into CTE, it's hard not to think of the Untreated Syphilis Study at Tuskegee. For forty years between 1932 and 1972, the U.S. Public Health Service (USPHS) observed the natural history of untreated syphilis in hundreds of black men. Researchers did not offer treatment, even though penicillin, a cure for syphilis, became widely available after 1946. In addition to the 128 participants who died from syphilis or related complications, the withholding of the antibiotic also led to the infection of 40 wives and the birth of 19 children with congenital syphilis. The parallel is that CTE is a disease with a beginning, followed by symptoms that are observable, even without a diagnosis. Humans learn to avoid or limit exposure to situations or environments where they may pick up a disease. Even without a doctor's diagnosis, victims and people close to them notice sickness. Moms and dads of children suffering from lingering concussion symptoms don't have to rely on a medical system that lacks awareness about healing modalities like Hyperbaric Oxygen Therapy (HBOT). It's as true for adults and athletes. CAPITALISM IN THE SADDLE: Research Pays Better Than "Cures" When There's No Drugs Involved There's a growing set of researchers devoting themselves to the study of CTE. There's no lack of brains for the forensic pathologists. What with the new "sports" of Slap Fighting, and "Run It Straight" and the broadening appeal of Mixed Martial Arts, there's money to be made in "Commercializing Concussion," as the BBC puts it. There's growing funding for Brain Banks. There isn’t a definitive count of all organizations studying Chronic Traumatic Encephalopathy (CTE) in the U.S., but several major institutions and research consortia are leading the charge. Here are some of the most prominent:  1. UNITE Brain Bank (Boston University) - One of the largest CTE brain banks in the world. - Has studied over 1,300 donated brains, primarily from athletes and veterans.  2. VA-BU-CLF Brain Bank - A collaboration between the U.S. Department of Veterans Affairs, Boston University, and the Concussion Legacy Foundation. - Focuses on military and sports-related brain trauma.  3. NIH/NINDS (National Institute of Neurological Disorders and Stroke) - Funds and conducts research on CTE and traumatic brain injury (TBI). - Supports the TRACK-TBI and CONNECT-TBI studies, which include long-term tracking of brain injury outcomes.  4. Mayo Clinic Brain Bank - Conducts neuropathological studies on CTE and other neurodegenerative diseases. - Has published findings on CTE in amateur athletes.  5. Mount Sinai Brain Bank - Investigates neurodegenerative diseases, including CTE, with a focus on molecular and genetic mechanisms.  6. University of Pennsylvania’s Center for Brain Injury and Repair - Studies the long-term effects of TBI and potential links to CTE. 7. NIH NeuroBioBank. Several international organizations are actively studying Chronic Traumatic Encephalopathy (CTE), especially as awareness of sports-related brain injuries grows worldwide. Here are some:  1. The Concussion in Sport Group (CISG) - An international panel of experts that produces the Consensus Statement on Concussion in Sport, widely used to guide concussion protocols globally . - Their work influences CTE research by shaping how head injuries are recognized and managed in sports.  2. Canadian Concussion Centre (Toronto Western Hospital) - Conducts research on long-term effects of concussions, including CTE. - Collaborates with international partners and has published studies on neuropathology in athletes.  3. Australian Sports Brain Bank - Collects and studies brains from athletes exposed to repetitive head trauma. - Has identified CTE pathology in former rugby and Australian rules football players, contributing to global understanding of the disease.  4. UK Brain Bank for Dementia Research - While not exclusively focused on CTE, it supports research into neurodegenerative diseases, including those linked to traumatic brain injury. - British universities like University College London (UCL) are also involved in CTE-related studies.  5. International Concussion and Head Injury Research Foundation (ICHIRF) - Based in London, it studies long-term effects of sports-related head injuries in jockeys, rugby players, and other athletes. - Works with global partners to track cognitive and neurological outcomes.  6. World Rugby and FIFA Medical Research Programs - These governing bodies fund and collaborate on research into head injury prevention and long-term effects, including CTE. - Their findings influence global sports safety policies. CTE is a brain wound, and Treatment is Available CTE might start with the first Concussion. Recent research on acute concussions by Dr Daphne Denham demonstrates brain wound healing and symptom reduction/eradication within four Hyperbaric Oxygen sessions. There's simply no excuse for medicine and the CTE-industry to continue to avoid a treatment with such scientific and clinical validation worldwide. Forensic pathology will continue to add to the identification of CTE-infected brains, but their work will not bring back the victims. Using some of their talents on early-stage treatment intervention, while it will reduce the number of brains they have to analyze, will prove of inestimable help to those suffering a deteriorating quality of life. Sadly, as with suicide prevention, lamenting the epidemic of concussions and CTE with "thoughts and prayers" and mere symptom reduction slips close to negligent behavior. ********************************** Quick FOOTNOTE in a CASE STUDY: Bringing it home for Veterans. Researchers studying US Naval Special Warfare Combatant Crewmen (SWCC boat operators) asked a question: Can exposures to dynamic forces sustained by US Naval special warfare combatant crewmen (SWCC), including repetitive, high-speed boat impacts with waves, predispose them to chronic traumatic encephalopathy (CTE)? It is worth quoting from their findings: "In this neuropathological case study of a deceased, 44.9-year-old SWCC operator who served a 12-year career with at least 4 combat deployments, we report severe CTE. . . . it is our interpretation that occupational exposures of a SWCC career, including prolonged and extensive exposure to repetitive physical forces applied to the head from high-speed boat impacts with waves, may be sufficient to promote or otherwise contribute to the development of CTE." The Navy suicide rate is at a four-year high. Our on-going successful HBOT treatments of multiple SWCC operators confirms that we can interrupt the concussion cascade that can lead to CTE, and reduce the suicide rate. Heal Brains. Stop Suicides. Restore Lives. TreatNOW ****************************** The TreatNOW Mission is ending service member suicides. Along the way, we have learned that we can end suicidal ideation, help end symptoms of PTSD, get patients off most of their drugs, and heal brain wounds to end the effects of Concussion, BLAST injury, mild TBI Persistent Post Concussive Syndrome, and polytrauma from AHI, Burn Pits, and COVID. No Veteran or civilian has ever been killed while undergoing HBOT treatment for TBI/PTSD. Read the full article

[business-market-insight]

North America Narcolepsy Market, Size, Segment and Growth by Forecast Period: (2019-2027)

North America Narcolepsy Market Outlook

The North America narcolepsy market is projected to grow from US$ 919.6 million in 2018 to US$ 2,024.8 million by 2027, at a CAGR of 9.3% from 2019 to 2027. 📚Download Full PDF Sample Copy of Market Report @ https://wwcw.businessmarketinsights.com/sample/TIPRE00008100

This growth is primarily driven by the rising prevalence of sleep disorders and the expansion of the pharmaceutical industry. However, the market faces a significant challenge—the absence of a definitive cure for narcolepsy, which limits treatment outcomes to symptom management.

Narcolepsy is a chronic neurological disorder that affects the brain’s ability to regulate sleep-wake cycles. It can manifest at any age, most commonly between 17 to 25 years, and presents symptoms such as excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations. It is considered the second leading cause of excessive daytime sleepiness in the North American population.

According to the National Organization for Rare Disorders, narcolepsy affects approximately 1 in every 2,000 people. The National Institute of Neurological Disorders and Stroke estimates that between 135,000 and 200,000 Americans are currently living with narcolepsy.

The growing incidence of sleep-related conditions is affecting productivity and quality of life across all age groups. In children, it impacts academic performance; in adults, it reduces workplace efficiency; and in older individuals, it increases health risks, such as sleep-related breathing disorders.

A 2018 study published by Oxford Academics found that narcolepsy occurs more frequently in women and is most prevalent among individuals aged 21–30 years. It is also believed that genetic predisposition combined with environmental exposures may trigger the onset of narcolepsy.

Sleep disorders have become a widespread health concern in North America. Over 50 million people in the region suffer from more than 80 distinct sleep disorders, and an estimated 20 to 30 million experience recurring sleep disturbances each year. This growing demand for effective treatment options is expected to significantly boost the narcolepsy market over the coming years.

Strategic Insights: North America Narcolepsy Market

Strategic insights into the North America narcolepsy market deliver a comprehensive, data-driven analysis of the evolving industry landscape. These insights explore current trends, key market players, and regional dynamics, offering stakeholders a clear understanding of where opportunities lie. By identifying underserved segments and uncovering potential for unique value propositions, businesses can gain a competitive edge.

Through the use of advanced data analytics, these insights help investors, manufacturers, and other market participants stay ahead of emerging shifts and make proactive, well-informed decisions. A forward-looking approach ensures that stakeholders are not only reacting to market changes but are also strategically positioned for long-term growth and resilience in this dynamic sector.

Ultimately, these insights are designed to support effective decision-making that enhances profitability and drives sustainable success across the North America narcolepsy market.

Market leaders and key company profiles   Teva Pharmaceutical Industries Ltd.

  Jazz Pharmaceuticals plc

  Arena Pharmaceuticals, Inc.

  Graymark Healthcare, Inc.

  Novartis AG

  Takeda Pharmaceutical Company Limited

  Mylan N.V.

  BIOPROJET

  Shionogi & Co., Ltd.

  Ligand Pharmaceuticals, Inc North America Narcolepsy Market – Regional Insights The geographic scope of the North America narcolepsy market encompasses the distinct regions where businesses operate and compete. Understanding regional differences—such as variations in patient demographics, healthcare infrastructure, economic conditions, and regulatory frameworks—is essential for developing market-specific strategies. Companies can unlock growth opportunities by identifying underserved areas and adapting their products or services to meet local needs. A well-defined regional focus enables more efficient resource allocation, precise marketing efforts, and stronger positioning against local competitors, ultimately accelerating market penetration and business expansion. About Us: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications Author's Bio Akshay Senior Market Research Expert at Business Market Insights

[unicausnews]

Jun 23, 2025 06:42 PM IST Here's all the things it's good to find out about Salman Khan's medical points that the actor casually revealed on Kapil Sharma's present final weekends A couple of months in the past, Bollywood’s Bhaijaan Salman Khan left his many followers apprehensive along with his look in viral movies. Many netizens questioned if Bhaijaan was dealing with well being points, however they took a breath of reduction when the actor clarified that he regarded this manner attributable to sleep deprivation and a busy schedule. However, final weekend when Salman graced the primary episode of The Great Indian Kapil Show season 3, he gave followers a trigger to fret once more as he casually revealed medical points that he's at present battling. The famous person shared that he has a mind aneurysm, trigeminal neuralgia and AV malformation. But what do these phrases imply and the way severe is his situation? Salman Khan on Kapil Sharma's present According to the Mayo Clinic, a mind aneurysm is a bulge or ballooning in a blood vessel within the mind. If the mind aneurysm leaks or ruptures, it causes bleeding within the mind, which is called a hemorrhagic stroke. Even although a mind aneurysm is widespread, if it ruptures it will probably change into life-threatening. Trigeminal neuralgia, then again, is a persistent ache situation which causes intense ache, like an electrical shock, on one facet of the face. It impacts the nerve which carries alerts from the face to the mind. The ache will be triggered even by mild exercise resembling brushing tooth or making use of make-up. Meanwhile, the National Institute of Neurological Disorders and Stroke describes AV malformation as an irregular tangle of blood vessels that causes issues with the connections between your arteries and veins. It most frequently happens within the spinal wire and within the mind however can develop elsewhere within the physique as effectively. During his look on Kapil Sharma’s comedy present, speaking about current divorce and alimony circumstances within the society, Salman shared, “Hum ye jo every day ki haddiyaan tudwa rahe hain, pasliyaan toot gai, trigeminal neuralgia ke sath kaam kar rahe hain, aneurysm hai mind mein uske bawajood kaam kar rahe hain. AV malformation hai, uske bawajood chal rahe hain. All of this is happening in my life. Aur jahan unka temper satka, woh aadha humara leke chala gaya.” We hope Bhaijaan takes excellent care of himself as he prepares to bounce again on the silver display screen quickly. Read More: https://news.unicaus.in/entertainment/salman-khan-reveals-he-has-a-mind-aneurysm-trigeminal-neuralgia-and-av-malformation-what-are-these-medical-points/

[kanagahospitals]

Kanaga Hospitals: Redefining Multispeciality Healthcare in Chennai

Chennai, a bustling metropolis known for its world-class medical infrastructure, is home to many renowned healthcare institutions. Among them, Kanaga Hospitals stands out as a trusted name in multispeciality care, offering a wide range of advanced treatments and services with a patient-first approach. With a focus on compassionate care, cutting-edge technology, and clinical excellence, Kanaga Hospitals has carved a niche for itself in the city’s healthcare landscape.

Comprehensive Multispeciality Services Under One Roof

Kanaga Hospitals offers a broad spectrum of medical services across several specialities, making it a one-stop solution for patients seeking quality care. From general medicine to advanced surgical interventions, the hospital ensures that patients receive holistic treatment under the supervision of experienced specialists.

Key departments include:

Cardiology and Cardiothoracic Surgery: Equipped with advanced diagnostic tools and cath labs, the hospital handles both emergency and elective cardiac procedures.

Orthopaedics and Joint Replacement: Known for minimally invasive surgeries and state-of-the-art rehabilitation, Kanaga Hospitals treats fractures, sports injuries, arthritis, and more.

Neurology and Neurosurgery: Skilled neurologists and neurosurgeons manage conditions like stroke, epilepsy, brain tumors, and spinal disorders.

Gastroenterology, Urology, Pulmonology, and Endocrinology: Each department functions with a multidisciplinary approach, ensuring tailored treatment for complex cases.

Additionally, Kanaga Hospitals offers dedicated units for maternity and child care, oncology, and nephrology, alongside 24/7 emergency and critical care services. Diagnostic facilities including MRI, CT, and pathology labs support accurate and timely diagnosis.

Patient-Centric Approach with Advanced Infrastructure

What sets Kanaga Hospitals apart is its strong commitment to patient comfort and care. Every aspect of the hospital—from its well-designed outpatient departments to its modern intensive care units—is built with the patient in mind. The facility includes:

Spacious consultation rooms and waiting areas

Fully equipped operation theatres

Private and semi-private patient rooms with modern amenities

A 24-hour pharmacy and ambulance service

The hospital invests consistently in technology and innovation, utilizing digital health records, telemedicine options, and AI-supported Multispeciality Hospitals diagnostic tools to improve treatment outcomes. Its nursing staff and support teams are trained to deliver compassionate care, making hospital visits less stressful for both patients and families.

Moreover, Kanaga Hospitals follows stringent hygiene and safety protocols, especially in the wake of recent global health challenges. This focus on quality and safety has earned the trust of patients across Chennai and surrounding regions.

A Vision for Healthier Communities

Kanaga Hospitals is not just a centre for treatment—it's a proactive force in building a healthier society. The hospital regularly conducts:

Health awareness camps

Free medical check-ups

Vaccination drives

Preventive health workshops for schools, colleges, and corporate offices

Through these initiatives, Kanaga Hospitals reaches out to the wider community, promoting early diagnosis and healthy lifestyle choices.

The hospital also places emphasis on continuous medical education for its staff and encourages collaboration with national and international medical bodies. This culture of learning ensures that the team stays updated with the latest advancements in medical science and patient care practices.

Looking to the future, Kanaga Hospitals aims to expand its footprint, add new specialities, and enhance its infrastructure while continuing to uphold its core values of integrity, empathy, and excellence.

Conclusion

With its comprehensive range of services, modern facilities, and compassionate care, Kanaga Hospitals has earned its reputation as one of the leading multispeciality hospitals in Chennai. Whether it's a routine health check-up or a complex surgery, patients can trust Kanaga Hospitals to deliver high-quality, personalized medical care every step of the way.

[cruelpendulumspell]

Nerve Freedom: A New Frontier for Healthcare in the United States

Introduction

In the modern age of healthcare, one of the most overlooked yet debilitating aspects of human suffering is nerve-related pain and dysfunction. Millions of Americans silently endure conditions like neuropathy, sciatica, multiple sclerosis, or spinal cord injuries — all of which can have a profound impact on mobility, autonomy, and quality of life. “Nerve Freedom” is a growing movement within the United States that calls for a more comprehensive approach to understanding, treating, and advocating for individuals afflicted with neurological disorders. This movement represents not only medical progress but also a call for social justice, innovation, and systemic reform in healthcare policy.

👉👉➣ Buy Now with Huge Discount ⥤⥤ Official Website Visit Now ️️👈👈

Understanding the Crisis

Nerve disorders affect nearly 20 million Americans, according to data from the National Institute of Neurological Disorders and Stroke. Yet, these conditions often remain undiagnosed or misdiagnosed for years. Patients suffer from chronic pain, numbness, tingling, burning sensations, and muscle weakness, all of which can erode their mental health and productivity. What’s worse, the cost of managing nerve conditions is staggering — not just for individuals, but for the nation’s healthcare system. In 2023 alone, Americans spent over $60 billion treating nerve-related conditions.

Despite the magnitude of the issue, nerve health has not been given the same spotlight as diseases like cancer, diabetes, or heart conditions. This is partly because nerve disorders are complex and difficult to treat. The nervous system is intricate and often resistant to healing once damaged. Nevertheless, this is not a reason for inaction — it’s a call to innovate and prioritize nerve health in national healthcare strategies.

The Birth of the "Nerve Freedom" Movement

"Nerve Freedom" is not merely a slogan — it is a declaration of independence for patients trapped in bodies that no longer serve them well. It is a grassroots campaign spearheaded by advocates, neurologists, researchers, and patients who demand better treatment protocols, greater funding for neurological research, and more inclusive insurance coverage.

The term “Nerve Freedom” captures the vision of reclaiming bodily autonomy and quality of life through access to cutting-edge diagnostics, personalized care, regenerative medicine, and public education. At its core, it is a civil rights issue — everyone deserves the right to live free from preventable or treatable suffering.

👉👉➣ Buy Now with Huge Discount ⥤⥤ Official Website Visit Now ️️👈👈

Medical Breakthroughs and Hope on the Horizon

One of the most exciting aspects of the Nerve Freedom movement is the surge in medical research and innovation. Over the past decade, science has made significant strides in understanding the nervous system and how it can be repaired. Some of the most promising breakthroughs include:

1. Stem Cell Therapy

Researchers are increasingly turning to stem cells to regenerate damaged nerve tissue. Clinical trials in the U.S. and abroad are exploring the use of stem cells to treat spinal cord injuries, peripheral neuropathy, and even neurodegenerative diseases. While stem cell therapies are still in their experimental stages, early results are encouraging and show the potential to dramatically restore function.

2. Neuroprosthetics and Brain-Computer Interfaces

Technologies such as brain-computer interfaces (BCIs) and advanced neuroprosthetics are changing what it means to live with nerve damage. From robotic arms controlled by thought to spinal implants that help paraplegics walk, the gap between science fiction and reality is closing rapidly. These innovations provide a glimpse into a future where nerve injury no longer means permanent disability.

3. Gene Editing and CRISPR

CRISPR technology has opened the door to correcting genetic defects that lead to conditions like Charcot-Marie-Tooth disease, ALS, or inherited neuropathies. Though ethical and technical hurdles remain, gene editing holds immense promise for eliminating hereditary neurological disorders at their root.

4. Targeted Drug Development

Big Pharma is beginning to pay attention to nerve-related conditions, especially neuropathic pain. Drugs that target specific ion channels or inflammatory pathways offer better relief than traditional opioids — without the risks of addiction and tolerance.

👉GET Nerve Freedom from the Official Website to Get Up to 75% DISCOUNT NOW👈 {Click here to official website Lowest Price}

The Policy Gap: Why the U.S. Must Act Now

Despite the progress in research and technology, a significant barrier remains: access. Many patients cannot afford cutting-edge treatments, and insurance companies often categorize nerve conditions as “chronic” or “non-curable,” which limits coverage options. Additionally, the lack of standardized diagnostic tools means patients are often dismissed or misdiagnosed, further delaying treatment.

The U.S. healthcare system must evolve to accommodate the needs of those living with nerve disorders. This includes:

Universal Insurance Coverage for Nerve Conditions Coverage must include physical therapy, assistive technology, and alternative treatments like acupuncture and nerve stimulation, which have been proven effective.

Increased Federal Funding for Neurological Research NIH and other federal agencies should allocate a larger share of research grants to neurological diseases and innovative treatments.

National Registry and Awareness Programs A centralized registry for nerve disorder cases would help track prevalence and outcomes, improving epidemiological understanding and resource allocation.

Disability Rights and Workplace Protections Nerve disorders often lead to hidden disabilities. Stronger workplace protections, remote work policies, and rehabilitation programs can help affected individuals stay employed and economically independent.

The Human Story: Lives Transformed

The most powerful argument for Nerve Freedom comes not from statistics but from the lives it touches. Take the story of James Martinez, a 34-year-old veteran from Texas who suffered a spinal cord injury during deployment. For years, James was wheelchair-bound and battled severe depression. Through a VA-funded trial using spinal cord stimulation, James regained partial mobility and now advocates for veterans’ access to neurotechnology.

Or consider Anika Sharma, a teenager from California living with peripheral neuropathy caused by chemotherapy. Her school initially failed to accommodate her physical limitations, but after her family connected with advocacy groups, they were able to secure educational accommodations and physical therapy through public health programs.

These stories show that with the right tools and policies, nerve damage doesn’t have to be a life sentence.

👉GET Nerve Freedom from the Official Website to Get Up to 75% DISCOUNT NOW👈 {Click here to official website Lowest Price}

The Role of Education and Public Perception

Another major challenge in achieving Nerve Freedom is public perception. Many people — including some in the medical community — downplay nerve pain or assume it’s a symptom of aging. This stigma leads to delayed diagnosis, under-treatment, and patient frustration.

To change this narrative, public awareness campaigns must be launched nationwide. These campaigns should highlight:

Early signs of nerve conditions

The importance of timely intervention

Advances in medical technology

Stories of recovery and hope

Educational institutions should also incorporate nerve health into basic health curricula to ensure that future generations understand and prioritize neurological well-being.

The Global Context

While the Nerve Freedom movement is gaining traction in the U.S., it resonates globally. Countries like Sweden and Japan are investing heavily in neurotechnologies, while international collaborations are driving the science of nerve regeneration forward. By aligning with global efforts, the U.S. can position itself as a leader in neuro-health innovation, creating jobs, saving lives, and improving its standing in medical diplomacy.

The Road Ahead

Achieving Nerve Freedom in the United States won’t happen overnight. It requires coordinated effort across sectors: medical, political, educational, and technological. But the momentum is building. Advocacy groups are mobilizing, researchers are innovating, and patients are refusing to be silent any longer.

We stand on the threshold of a revolution — one where pain no longer rules lives, and broken bodies are met not with resignation, but with the tools of renewal. The fight for Nerve Freedom is the fight for dignity, for health equity, and for the limitless potential of human resilience.

Conclusion

Nerve Freedom is more than a medical mission — it is a moral imperative. As a nation, the United States has the resources, talent, and ingenuity to lead the world in transforming the lives of those affected by neurological disorders. The question is not whether we can — it is whether we will.

Every voice raised in awareness, every dollar spent in research, and every policy changed in favor of access and inclusion brings us closer to a future where freedom from nerve pain is not a privilege but a right. It’s time to make Nerve Freedom a national priority.

👉GET Nerve Freedom from the Official Website to Get Up to 75% DISCOUNT NOW👈 {Click here to official website Lowest Price}

Nerve Freedom

Nerve Freedom is more than a medical mission — it is a moral imperative. As a nation, the United States has the resources,